Raymond James Initiates Coverage On Vera Therapeutics with Outperform Rating, Announces Price Target of $29
Portfolio Pulse from Benzinga Newsdesk
Raymond James analyst Steven Seedhouse has initiated coverage on Vera Therapeutics (NASDAQ:VERA) with an Outperform rating and set a price target of $29.
December 18, 2023 | 1:13 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Vera Therapeutics received an Outperform rating from Raymond James with a price target of $29.
Analyst ratings, especially from reputable firms like Raymond James, can significantly influence investor sentiment and stock prices in the short term. The Outperform rating suggests that the analyst believes VERA will perform better than the market or its sector, which could lead to increased investor interest and a potential rise in the stock price. The price target of $29 indicates a substantial upside from the current trading price, assuming the stock is trading below this target.
CONFIDENCE 90
IMPORTANCE 85
RELEVANCE 100